Last reviewed 2026-04-22 · How we verify

Non DPP-4 Inhibitor

A non-DPP-4 inhibitor that works through an alternative mechanism to manage blood glucose levels in diabetes, distinct from dipeptidyl peptidase-4 inhibition.

A non-DPP-4 inhibitor that works through an alternative mechanism to manage blood glucose levels in diabetes, distinct from dipeptidyl peptidase-4 inhibition. Used for Type 2 diabetes mellitus.

At a glance

Mechanism of action

This drug operates outside the DPP-4 inhibitor class, meaning it does not inhibit the dipeptidyl peptidase-4 enzyme. Without additional specificity on the exact mechanism from Chung-Ang University's research, the precise target pathway remains unclear, but it is positioned as a marketed antidiabetic agent with a differentiated mechanism of action from DPP-4 inhibitors.

Approved indications

• Type 2 diabetes mellitus

Common side effects

No common side effects on file.

Key clinical trials

• Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
• Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis (PHASE4)
• Oral Anti Diabetic Agents in the Hospital (PHASE4)
• A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
• LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes (NA)
• DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes (PHASE3)
• Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk
• DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.